Morgan Stanley Maintains Overweight on Bicara Therapeutics, Raises Price Target to $37

Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $36 to $37.